This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

PSMA Affiline

n.c.a. 177Lu-DOTA-Affilin / 68Ga-DOTA-Affilin

ITM and its partner Navigo Proteins cover within a strategic cooperation a number of programs for the discovery and development of novel targeted radio conjugates for imaging and therapy purposes, in a variety of indications. Navigo Proteins will be responsible for the discovery and design of the radio conjugates based on its proprietary Affilin® platform, while ITM will use its radioisotope technology and be responsible for later-stage development of the resulting products. The first program has commenced in the area of targeted cancer treatment.

Navigo Proteins with its Affilin® platform delivers compounds with precisely engineered carriers, whereas ITM selects the compounds half-lives, short-term for imaging applications and longer-term for therapeutic applications.

Affilin® artificial proteins have the ability to selectively bind antigens. They are derived from human scaffold proteins and have high stability, affinity, and specificity making them an ideal platform for a range of applications, including those where antibodies have limitations, thus broadening the potential of biotherapeutics.